Press Releases

May 16, 2016
VistaGen Completes $10 Million Public Offering

May 10, 2016
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering

March 30, 2016
VistaGen Therapeutics Appoints Jerry Gin, Ph.D., MBA to its Board of Directors

March 22, 2016
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression

December 23, 2015
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network

November 3, 2015
VistaGen Announces First Patient Dosed in NIH-Sponsored Phase 2A Study of Orally Available AV-101 in Major Depressive Disorder

October 7, 2015
Dr. Maurizio Fava, Internationally Renowned Expert in the Field of Depression, Joins VistaGen’s Clinical and Scientific Advisory Board

September 16, 2015
Favorable Data on VistaGen Therapeutics’ AV-101 for Major Depressive Disorder Published in Peer-reviewed Journal of Pharmacology and Experimental Therapeutics

July 1, 2015
VistaGen Receives FDA and NIH Clearance to Initiate NIH-Funded Phase 2 Study of Orally Active AV-101 in Major Depressive Disorder

February 17, 2015
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder

February 5, 2015
Dr. Gerard Sanacora Joins VistaGen’s Clinical and Scientific Advisory Board

2015 | 2014 | 2013 | 2012 | 2011